{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:49:31Z","timestamp":1793724571765,"version":"4.6.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022274","name":"Daiichi Sankyo Europe GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.breast.2026.104721","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T15:58:08Z","timestamp":1770479888000},"page":"104721","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Real-world treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States"],"prefix":"10.1016","volume":"86","author":[{"given":"Shanu","family":"Modi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8754-0530","authenticated-orcid":false,"given":"Danalyn","family":"Byng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Dunton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Jacot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.breast.2026.104721_bib2","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104721_bib3","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1200\/JCO.24.00248","article-title":"Endocrine and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer-capivasertib-fulvestrant: ASCO rapid recommendation update","volume":"42","author":"Burstein","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4_Supplement","key":"10.1016\/j.breast.2026.104721_bib4","first-page":"GS4","article-title":"Abstract GS4-01: results from CONTESSA: a phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane","volume":"81","author":"O\u2019Shaughnessy","year":"2021","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.breast.2026.104721_bib5","article-title":"Efficacy and safety of weekly paclitaxel with or without oral alisertib in patients with metastatic breast cancer: a randomized clinical trial","volume":"4","author":"O'Shaughnessy","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"20","key":"10.1016\/j.breast.2026.104721_bib6","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.breast.2026.104721_bib7","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","article-title":"ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer","volume":"34","author":"Tarantino","year":"2023","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.breast.2026.104721_bib8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.5858\/arpa.2012-0617-OA","article-title":"A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology\/College of American Pathologists criteria","volume":"138","author":"Schalper","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.breast.2026.104721_bib9","unstructured":"United States Food and Drug Administration. Enhertu - Highlights of prescribing information. https:\/\/daiichisankyo.us\/prescribing-information-portlet\/getPIContent?productName=Enhertu&inline=true;2019. [Accessed 7 April 2025]."},{"issue":"22","key":"10.1016\/j.breast.2026.104721_bib11","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104721_bib12","series-title":"ESMO Metastatic Breast Cancer Living Guideline","author":"Gennari","year":"2025"},{"key":"10.1016\/j.breast.2026.104721_bib14","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10549-025-07649-y","article-title":"Treatment patterns and outcomes in HER2-low metastatic breast cancer patients previously treated with chemotherapy: a US real-world cohort study","author":"Modi","year":"2025","journal-title":"Breast Cancer Res Treat"},{"issue":"21","key":"10.1016\/j.breast.2026.104721_bib21","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.3390\/cancers17213505","article-title":"Trastuzumab-Deruxtecan for the treatment of metastatic breast cancer patients: data from real world studies","volume":"17","author":"Quaquarini","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.breast.2026.104721_bib22","first-page":"863","article-title":"Efficacy of Trastuzumab Deruxtecan in HER2-positive and HER2-low metastatic breast cancer: a real-world retrospective cohort study in China","volume":"17","author":"Yan","year":"2025","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"10.1016\/j.breast.2026.104721_bib15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2021.05.008","article-title":"Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial","volume":"154","author":"Guarneri","year":"2021","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.breast.2026.104721_bib16","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1158\/2159-8290.CD-20-1647","article-title":"Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative","volume":"11","author":"Aftimos","year":"2021","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.breast.2026.104721_bib17","first-page":"353","article-title":"The difference in prognostic outcomes between De Novo stage IV and recurrent metastatic patients with hormone receptor-positive, HER2-negative breast cancer","volume":"32","author":"Yamamura","year":"2018","journal-title":"In Vivo (Athens)"},{"key":"10.1016\/j.breast.2026.104721_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104412","article-title":"Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancer","volume":"80","author":"Walter","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104721_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115113","article-title":"The journey of patients affected by metastatic hormone receptor-positive\/HER2-negative breast cancer from CDK 4\/6 inhibitors to second-line treatment: a real-world analysis of 701 patients enrolled in the GIM14\/BIOMETA study","volume":"213","author":"Molinelli","year":"2024","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.breast.2026.104721_bib20","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/oncolo\/oyad035","article-title":"Real-World evaluation of disease progression after CDK 4\/6 inhibitor therapy in patients with hormone receptor-positive metastatic breast cancer","volume":"28","author":"West","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2026.104721_bib25","article-title":"FDA approves abemaciclib for HR-positive","year":"2017","journal-title":"HER2-negative breast cancer"},{"issue":"2","key":"10.1016\/j.breast.2026.104721_bib26","doi-asserted-by":"crossref","first-page":"e2461067","DOI":"10.1001\/jamanetworkopen.2024.61067","article-title":"Survival following CDK4\/6 inhibitor therapy for hormone receptor\u2013positive, ERBB2\u2013negative metastatic breast cancer","volume":"8","author":"Berton","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.breast.2026.104721_bib27","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s12282-025-01713-7","volume":"32","author":"Yoshinami","year":"2025","journal-title":"Breast Cancer"},{"issue":"22","key":"10.1016\/j.breast.2026.104721_bib28","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American pathologists Guideline update","volume":"41","author":"Wolff","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104721_bib29","doi-asserted-by":"crossref","DOI":"10.1155\/tbj\/5577345","article-title":"Clinical outcomes of CDK4\/6 inhibitor therapy in HR+\/HER2- metastatic breast cancer: a multicenter comparison of HER2-low and HER2-zero subgroups","volume":"2025","author":"Ozcan","year":"2025","journal-title":"Breast J"},{"issue":"2","key":"10.1016\/j.breast.2026.104721_bib30","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00404-024-07761-2","article-title":"Impact of low HER2 expression on response to CDK4\/6 inhibitor treatment in advanced HR +\/HER2- breast cancer: a multicenter real-world data analysis","volume":"311","author":"Ralser","year":"2025","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.breast.2026.104721_bib31","doi-asserted-by":"crossref","DOI":"10.1155\/ijbc\/5597051","article-title":"Clinical outcomes of HER2-Low versus HER2-zero in HR-positive metastatic breast cancer treated with endocrine therapy with or without CDK4\/6 inhibitors: a multicenter retrospective study","volume":"2025","author":"Susiriwatananont","year":"2025","journal-title":"Int J Breast Cancer"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T21:30:26Z","timestamp":1775683826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626000317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":26,"alternative-id":["S0960977626000317"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104721","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104721","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104721"}}